BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need.

Aging drives the chronic diseases that are the biggest burden on the medical system, and BYOMass, Inc. has built a compelling case around modulating defined targets to alleviate multi-morbidity.

BYOMass was founded by Dr. Margaret Jackson, who has led multiple teams and drug discovery efforts in her twenty-year career as a drug developer. Dr. Jackson leads BYOMass as Founder and CEO. 

 For more information, visit BYOMassTx.com